Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

Delayed Quote. Delayed  - 06/24 10:00:03 pm
14.38 USD   -7.46%
06/06 NEKTAR THERAPEU : Preclinical Data Presented at ASCO 2016 Annual Mee..
06/03 NEKTAR THERAPEU : ' President and CEO, Howard W. Robin, To Present a..
06/02 NEKTAR THERAPEU : Announces Executive Management Promotions
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/16/2016 | 07:12pm CEST

Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

By a News Reporter-Staff News Editor at Clinical Trials Week -- Nektar Therapeutics (NASDAQ: NKTR) announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016 (see also Nektar Therapeutics).

"These latest data build upon our growing body of preclinical evidence demonstrating the unique mechanism of NKTR-214," added Jonathan Zalevsky, PhD, Vice President, Biology and Preclinical Development at Nektar Therapeutics. "The studies presented at ASCO show that NKTR-214 promotes tumor-killing immune cell accumulation directly in the tumor, providing a mechanistic basis for its significant anti-tumor activity in multiple preclinical tumor models. The ability to grow TILs(1) in vivo and replenish the immune system is exceptionally important. We've now learned that many human tumors lack sufficient TIL populations and the addition of the NKTR-214 TIL-enhancing MOA could improve the success of many checkpoint inhibitors and other agents, and allow more patients to benefit from immuno-therapy."

In studies previously published for NKTR-214, when mice bearing established breast cancer tumors are treated with NKTR-214 and anti-CTLA4 (a checkpoint inhibitor therapy known as ipilimumab for human treatment), a large proportion of mice become tumor-free. Anti-tumor immune memory was demonstrated when tumor-free mice were re-challenged by implant with a new breast cancer tumor and then found to clear the new tumor, without further therapy. The new data presented at ASCO demonstrate that upon re-challenge, there is a rapid expansion of newly proliferative CD8 T cells and particularly CD8 effector memory T cells. Both cell populations were readily detectable in multiple tissues (blood, spleen, and lymph nodes) and likely contribute to the anti-tumor effect observed in these animals. Adoptive transfer studies confirmed the immune-memory effect as transplant of splenocytes from tumor-free mice into naive recipients provided the ability to resist tumor growth.

"NKTR-214 provides a highly unique immune activation profile that allows it to access the IL-2 pathway without pushing the immune system into pathological overdrive," said Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer. "NKTR-214's unique immune-stimulatory profile and antibody-like dosing schedule positions it as a potentially important medicine within the immuno-oncology landscape."

The data presentation at ASCO entitled, "Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor," can be accessed at http://www.nektar.com/2016_NKTR-214_ASCO_poster.pdf

NKTR-214 is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells by preferentially activating production of specific immune cells which promote tumor killing, including CD8-positive T cells and Natural Killer (NK) cells, within the tumor micro-environment. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these types of T cells.(2)

In preclinical studies, NKTR-214 demonstrated a highly favorable mean ratio of 450:1 within the tumor micro-environment of CD8-positive effector T cells relative to regulatory T cells.(3) Furthermore, the pro-drug design of NKTR-214 enables an antibody-like dosing regimen for an immuno-stimulatory cytokine.(4)

Keywords for this news article include: Cancer, Oncology, Cytokines, Immunology, Blood Cells, Lymphocytes, Pre-Trial Research, Nektar Therapeutics, Mononuclear Leukocytes, Hemic and Immune Systems, Clinical Trials and Studies, Intercellular Signaling Peptides and Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on NEKTAR THERAPEUTICS
06/16 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
06/09 NEKTAR THERAPEUTICS : and Daiichi Sankyo Europe GmbH Sign European Licensing Agr..
06/06 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
06/03 NEKTAR THERAPEUTICS : ' President and CEO, Howard W. Robin, To Present at the Je..
06/02 NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
06/02 NEKTAR THERAPEUTICS : Announces Executive Management Promotions
06/02 NEKTAR THERAPEUTICS : Studies from Nektar Therapeutics Further Understanding of ..
06/01 NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
06/01 NEKTAR THERAPEUTICS : and Daiichi Sankyo Europe GmbH Sign European Licensing Agr..
05/03 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials